Novartis AG – Filings and Transcripts

NYSE: NVS
Share price (9/30/26): $142.57
Market cap (9/30/26): $272 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

ended 12/31/24 FY 2024

ended 12/31/23 FY 2023

ended 12/31/22 FY 2022 – amended

ended 12/31/22 FY 2022

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Free writing prospectus

Prospectus supplement for primary offering

Registration of securities for employees

Amendment to registration of securities for employees

Ownership Filter

Bulto Carulla Victor

Bulto Carulla Victor

Tourmaline Bio Inc.

UBS AM, a Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

News Filter

Provides Update on Delpacibart Etedesiran (Del-Desiran) Phase III HARBOR Study for the Treatment of Myotonic Dystrophy Type 1

Announces Lp(a)HORIZON Phase III Topline Results for Pelacarsen in Patients With Elevated Lp(a) and Established Cardiovascular Disease

Remibrutinib, a High-Efficacy Oral BTK Inhibitor, Significantly Reduces Relapse Rates and Shows Favorable Safety Profile in Phase III RMS Trials

Financial Results | Finanzergebnisse

Delpacibart Braxlosiran (Del-Brax) Phase I/II Study in Facioscapulohumeral Muscular Dystrophy (FSHD) Meets Primary Biomarker Endpoint

Proxies Filter

Proxy materials by non-management

Proxy materials by non-management

Proxy materials by non-management

Proxy materials by non-management

Proxy materials by non-management

Other Filter

Notice required by Iran Threat Reduction and Syria Human Rights Act of 2012

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Notice required by Iran Threat Reduction and Syria Human Rights Act of 2012